⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HCWB News
HCW Biologics Inc. Common Stock
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
globenewswire.com
HCWB
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
globenewswire.com
HCWB
Form 8-K
sec.gov
HCWB
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
globenewswire.com
HCWB
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
prnewswire.com
ABBV
QTTB
HCWB
NKTR
LLY
INCY
PFE
Form 8-K
sec.gov
HCWB
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
globenewswire.com
HCWB
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
globenewswire.com
HCWB
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
globenewswire.com
HCWB
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
globenewswire.com
HCWB